Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer

US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ), today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

Read more here: http://www.prnewswire.com/news-releases/pre-clinical-studies-suggest-anisina-may-improve-chemotherapy-effectiveness-in-childhood-cancer-300111995.html